Antibiotic therapy may pose risk for stone disease
Anaheim, CA- Epidemiologists, puzzling over metabolism, diet, food supplements, and genes, may have to look no further than the medicine chest to find one of the factors contributing to the putative rise in kidney stone disease. Three studies presented here at the annual AUA meeting suggest a link between calcium oxalate stones, the bacterium Oxalobacter formigenes, and antibiotics.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.
Justin B. Ziemba, MD, discusses clinical factors that help identify patients at increased risk for kidney stone recurrence and guide metabolic evaluation.
Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.